XTLB xtlbio.com: Forward Price-to-Revenue Multiple
XTL Biopharmaceuticals develops treatments for autoimmune pathologies, relying on a debt-free balance sheet and prudent liquidity management. The forward P/S valuation illustrates market capitalization relative to future sales, where 12.70 indicates the level of this metric. Geopolitical tensions and sanctions are hindering the international certification of drugs. The current state of the business is characterized by asset restructuring in the absence of a stable stream of operating cash.
Comprehensive metric breakdowns and analytics for XTL Bio (XTLB)
- current price and projected stock value:
- company stock capitalization data:
- business book valuation details:
- company total debt and liquidity indicators:
Total Debt to Equity Ratio XTL Biopharmaceuticals|XTLB - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital XTL Biopharmaceuticals|XTLB - Company Debts|Debts to Book Capitalization XTL Bio|XTLB - Long-Term Debt Volume|Company Short-Term Debt XTL Biopharmaceuticals|Quick Liquidity xtlbio.com
- net income and valuation multiples indicators:
XTLB - Profit After Tax|Projected Future Earnings XTL Biopharmaceuticals|XTLB - Company Value to Net Income|Forward P/E Multiple XTL Biopharmaceuticals, Ltd.|XTLB - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization XTL Bio|XTLB - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months XTL Biopharmaceuticals|XTLB - Net earnings per share for the last 12 months|Quarterly EPS earnings growth xtlbio.com|XTLB - Earnings growth in current year|Earnings growth forecast for next year XTL Biopharmaceuticals
- issuer revenue and sales details:
Summary company analytics:XTL Biopharmaceuticals Ltd. XTLB
The biopharmaceutical sector's high sensitivity to central bank rates leaves the capitalization of XTL Biopharmaceuticals (XTLB) vulnerable to revisions in expected revenue. While reliable biomaterial logistics in trials mitigate operational risks, the forward P/S based on forecasts objectively measures the current market overvaluation of future cash flows, allowing investors to timely identify the gap between market optimism and the fundamental value of the assets.
Analysis of competing companies
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|ABVX: Forward Price-to-Revenue Multiple|ADMA (ADMA Corp) - Market Cap to Projected Revenue|PTGX (Protagonist Therapeutics) - Forward Price-to-Revenue Multiple|IMVT: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Kiniksa|Price-to-Projected Revenue Ratio GRFS|Forward Price-to-Revenue Multiple ADPT (Adaptive Biotechnologies Corp)|CLDX (Celldex Corp) - Forward Price to Sales|Forward P/S Multiple AUPH (Aurinia Pharmaceuticals)|biocryst.com - Price-to-Projected Revenue Ratio|Vera Therapeutics - Forward P/S Multiple|Market Cap to Expected Sales Ratio Dianthus Therapeutics Inc DNTH|Pharvaris Corp (PHVS) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio AbCellera Corp (ABCL)|Price-to-Projected Revenue Ratio Tourmaline Bio, Inc.|precigen.com - Future Price to Revenue|Forward P/S Multiple PHAR|NKTR (Nektar Therapeutics Inc) - Forward Price to Sales|Forward P/S Multiple UPB (Upstream Bio Corp)|Forward P/S Multiple Zenas Corp ZBIO|IMNM - Price-to-Projected Revenue Ratio|Forward Price to Sales GOSS (gossamerbio.com)|KalVista Pharmaceuticals, Inc. (KALV) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Septerna, Inc.|PVLA (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|Forward P/S Multiple Savara Pharma|Forward P/S Multiple RIGL|Forward Price-to-Revenue Multiple anaptysbio.com ANAB|Forward P/S Multiple ATXS (Astria Therapeutics, Inc.)|enGene Holdings Inc (ENGN) - Market Cap to Future Revenue Ratio|RAPT: Forward Price-to-Revenue Multiple|JBIO - Forward P/S Multiple|ACRS (Aclaris Therapeutics) - Forward Price-to-Revenue Multiple|KYTX: Price to Expected Revenue Ratio|TLSA (Tiziana Life Sciences Ltd) - Forward P/S Multiple|Cabaletta Bio Inc. (CABA) - Market Cap to Expected Sales Ratio|Forward P/S Multiple VTYX|Forward Price-to-Revenue Multiple Theratechnologies, Inc THTX|Forward P/S Multiple AVTX (Avalo Therapeutics, Inc)|Forward P/S Multiple eledon.com ELDN|AGEN - Price-to-Projected Revenue Ratio|CLYM: Price-to-Projected Revenue Ratio|Zura Bio Limited (ZURA) - Price-to-Projected Revenue Ratio|ATYR - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple ADAG|Market Cap to Projected Revenue IMA (Ikena Oncology, Inc.)|Forward Price-to-Revenue Multiple STTK (Shattuck Labs, Inc.)|Price to Expected Revenue Ratio EQ|Price-to-Projected Revenue Ratio Connect Biopharma Holdings Limited CNTB|Immunic Therapeutics - Price-to-Projected Revenue Ratio|Atara Biotherapeutics Inc - Forward P/S Multiple|IFRX: Price-to-Projected Revenue Ratio|X4 Pharmaceuticals, Inc. (XFOR) - Price-to-Projected Revenue Ratio|Future Price to Revenue ACET (Adicet Bio, Inc.)|CELU (Celularity Inc) - Forward P/S Multiple|INMB: Forward Price to Sales|Forward P/S Multiple BRNS|Forward P/S Multiple kezarlifesciences.com (KZR)|Price-to-Projected Revenue Ratio SAB Biotherapeutics, Inc. SABS|Forward Price to Sales AKTX|ENLV - Price-to-Projected Revenue Ratio|Q32 Bio Inc. (QTTB) - Forward Price-to-Revenue Multiple|GOVX: Forward P/S Multiple|edesabiotech.com (EDSA) - Forward P/S Multiple|Forward Price-to-Revenue Multiple IBIO|CARM: Forward Price to Sales|Forward P/S Multiple BOLT|Market Cap to Expected Sales Ratio hcwbiologics.com|Price-to-Projected Revenue Ratio Aptevo Therapeutics Inc. APVO|AIM - Forward Price-to-Revenue Multiple|ADTX - Price-to-Projected Revenue Ratio|GRI Bio Inc (GRI) - Forward Price-to-Revenue Multiple|XRTX (XORTX) - Forward Price-to-Revenue Multiple|Vyome Therapeutics (HIND) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Revelation Biosciences|Market Cap to Projected Revenue INDP (indaptusrx.com)|Forward P/S Multiple SCNI|CALI - Market Cap to Future Revenue Ratio|Affimed N.V. - Forward Price-to-Revenue Multiple|ALLK: Market Cap to Projected Revenue|HOOK: Forward Price-to-Revenue Multiple|IGM Biosciences, Inc. - Price to Expected Revenue Ratio|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|OCEA (Ocean Biomedical Inc) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple TCBP|THRD: Forward Price to Sales
